Chr Hansen HMO

Chr. Hansen HMO, now a core part of Novonesis following the 2024 merger with Novozymes, is a global leader in the research and production of Human Milk Oligosaccharides (HMOs). The company significantly expanded its capabilities in this sector through the 2020 acquisition of Jennewein Biotechnologie, a pioneer in HMO production. Utilizing advanced precision fermentation and metabolic engineering, the company produces complex carbohydrates that mimic those found in human breast milk to support infant health and adult gut wellness. Their portfolio includes key HMOs such as 2'-fucosyllactose and Lacto-N-neotetraose, which are supplied to major global infant formula manufacturers. The business focuses on the intersection of biotechnology and nutrition, aiming to improve the human microbiome from birth.